Drugs / MGD007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02248805 | Oct 2014 → Jul 2018 | colorectal carcinoma | MacroGenics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03531632 | Jun 2018 → Feb 2020 | colorectal cancer | MacroGenics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-07-24 | MacroGenics | Regulatory MacroGenics' DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients macrogenics.com ↗
MacroGenics' DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients |
| 2014-04-06 | MacroGenics | Results MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting macrogenics.com ↗
MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGD007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03531632 ↗ |
| Modality | Protein / enzyme biologic | “MGD007, a Humanized gpA33 × CD3 DART® Protein” NCT03531632 ↗ |
| Route | Intravenous | “MGD007 and MGA012 are administered by IV infusion.” NCT03531632 ↗ |